AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status

被引:3
|
作者
Long, Mengping [1 ]
You, Chong [2 ]
Song, Qianqian [3 ]
Hu, Lina X. J. [4 ]
Guo, Zhaorong [5 ]
Yao, Qian [1 ]
Hou, Wei [1 ]
Sun, Wei [1 ]
Liang, Baosheng [3 ]
Zhou, Xiaohua [2 ,3 ]
Liu, Yiqiang [1 ]
Hu, Taobo [2 ,6 ]
机构
[1] Peking Univ, Dept Pathol, Canc Hosp, Beijing 100083, Peoples R China
[2] Peking Univ, Chongqing Res Inst Big Data, Chongqing 401121, Peoples R China
[3] Peking Univ, Sch Publ Hlth, Dept Biostat, Beijing 100191, Peoples R China
[4] Alaska Native Med Ctr, Dept Pathol, Anchorage, AK 99501 USA
[5] Peking Univ, Dept Breast Ctr, Canc Hosp, Beijing 100083, Peoples R China
[6] Peking Univ Peoples Hosp, Dept Breast Surg, Beijing 100044, Peoples R China
基金
中国国家自然科学基金;
关键词
androgen receptor; estrogen receptor; breast cancer; molecular feature; ANDROGEN RECEPTOR EXPRESSION; PROGNOSIS; TUMORS;
D O I
10.3390/ijms231911468
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Androgen receptor (AR) expression is frequently observed in breast cancer, but its association with estrogen receptor (ER) expression in breast cancer remains unclear. This study analyzed the clinicopathological and molecular features associated with AR negativity in both ER-positive and ER-negative breast cancer, trying to elucidate the molecular correlation between AR and ER. Our results showed that AR negativity was associated with different clinicopathological characteristics and molecular features in ER-positive and ER-negative breast cancer. Moreover, AR-positive breast cancer has better clinicopathological features than AR-negative breast cancer, especially in the ER-negative subtype. These results suggest that the role of AR in ER-negative breast cancer is distinctive from that in ER-positive breast cancer.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] The expression status of TRX, AR, and cyclin D1 correlates with clinicopathological characteristics and ER status in breast cancer
    Huang, Weisun
    Nie, Weiwei
    Zhang, Wenwen
    Wang, Yanru
    Zhu, Aiyu
    Guan, Xiaoxiang
    ONCOTARGETS AND THERAPY, 2016, 9 : 4377 - 4385
  • [2] Androgen expression & clinicopathological features in male breast cancer
    Rebaza, Lia P.
    Castaneda, Carlos A.
    Castillo, Miluska
    Bernabe, Luis A.
    Sanchez, Joselyn
    Calderon, Gabriela
    Dunstan, Jorge
    de la Cruz, Miguel
    Cotrina, Jose M.
    Abugattas, Julio
    Guerra, Henry
    Villa-Robles, Maria R.
    Poma, Nathaly
    Mejia, Omar
    Gomez, Henry L.
    BREAST CANCER MANAGEMENT, 2018, 7 (01)
  • [3] Gene Expression Analyses of HER-2/neu and ESR1 in Patients with Breast Cancer
    Nadergoli, Omid Kheyri
    Feizi, Mohammad Ali Hosseinpour
    Kafil, Hossein Samadi
    Pouladi, Nasser
    Hosseinzadeh, Ali
    Rostamizadeh, Leila
    Montazeri, Vahid
    Fakhrjou, Ashraf
    Sakhinia, Ebrahim
    Seifi, Morteza
    BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY, 2017, 60
  • [4] Gene Expression Analyses of HER-2/neu and ESR1 in Patients with Breast Cancer
    Nadergoli, Omid Kheyri
    Feizi, Mohammad Ali Hosseinpour
    Kafil, Hossein Samadi
    Pouladi, Nasser
    Hosseinzadeh, Ali
    Rostamizadeh, Leila
    Montazeri, Vahid
    Fakhrjou, Ashraf
    Sakhinia, Ebrahim
    Seifi, Morteza
    BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY, 2018, 61
  • [5] Expression of Estrogen Receptor Alpha (ESR1) in Breast Cancer: Role in Critical Diagnosis
    Nayak, B. B.
    Achary, K. G.
    Singh, S.
    RESEARCH JOURNAL OF BIOTECHNOLOGY, 2022, 17 (02): : 143 - 148
  • [6] Clinical and Biological Significance of ESR1 Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients
    Nagel, Anna
    Szade, Jolanta
    Iliszko, Mariola
    Elzanowska, Julia
    Welnicka-Jaskiewicz, Marzena
    Skokowski, Jaroslaw
    Stasilojc, Grzegorz
    Bigda, Jacek
    Sadej, Rafal
    Zaczek, Anna
    Markiewicz, Aleksandra
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (08)
  • [7] RASEF expression correlates with hormone receptor status in breast cancer
    Shibata, Masahiro
    Kanda, Mitsuro
    Shimizu, Dai
    Tanaka, Haruyoshi
    Umeda, Shinichi
    Miwa, Takashi
    Hayashi, Masamichi
    Inaishi, Takahiro
    Miyajima, Noriyuki
    Adachi, Yayoi
    Takano, Yuko
    Nakanishi, Kenichi
    Takeuchi, Dai
    Noda, Sumiyo
    Kodera, Yasuhiro
    Kikumori, Toyone
    ONCOLOGY LETTERS, 2018, 16 (06) : 7223 - 7230
  • [8] AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer
    Liu, Dingxie
    CELLULAR ONCOLOGY, 2020, 43 (02) : 321 - 333
  • [9] Expression of eag1 channel associated with the aggressive clinicopathological features and subtype of breast cancer
    Liu, Guang-Xu
    Yu, Yun-Cui
    He, Xiang-Ping
    Ren, Sheng-Nan
    Fang, Xue-Dong
    Liu, Fen
    He, Yan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (11): : 15093 - 15099
  • [10] Expression and clinicopathological significance of FSIP1 in breast cancer
    Zhang, Hao
    Luo, Minna
    Jin, Zining
    Wang, Dan
    Sun, Ming
    Zhao, Xinhan
    Zhao, Zuowei
    Lei, Haixin
    Li, Man
    Liu, Caigang
    ONCOTARGET, 2015, 6 (12) : 10658 - 10666